RINVOQ 30 MG
UPADACITINIB : 30 MG · DIN 02520893 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is RINVOQ?
RINVOQ 30 MG contains UPADACITINIB : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02520893, held by ABBVIE CORPORATION, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RINVOQ used for?
Treatment of adults with RA, PsA, AS, nr-axSpA, GCA, UC, and Crohn’s disease; adults and adolescents (12+) with refractory moderate to severe atopic dermatitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02520893 |
|---|---|
| Brand name | RINVOQ |
| Generic / active ingredient | UPADACITINIB : 30 MG |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 30 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AF03 UPADACITINIB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Oct-2021 |
How is it administered?
RA, PsA, axSpA, GCA: 15 mg once daily. Atopic Dermatitis: 15 mg or 30 mg once daily. UC/Crohn's: 45 mg induction, then 15 mg or 30 mg maintenance. Swallow whole; do not crush/chew.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content cut off).
How is it supplied?
Not explicitly detailed in provided text (mentions 15 mg, 30 mg, and 45 mg tablets).
Contraindications
Hypersensitivity to upadacitinib or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious infections (TB, fungal, opportunistic), malignancies, thrombosis (DVT, PE, arterial), and major adverse cardiovascular events (MACE). Increased risk in patients 50+ with CV risk factors.
What can be used instead?
Other Canadian products sharing ATC code L04AF03 UPADACITINIB. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RINVOQ | 15 MG | TABLET (EXTENDED-RELEASE) | ABBVIE CORPORATION | MARKETED | DIN 02495155 |
| RINVOQ | 45 MG | TABLET (EXTENDED-RELEASE) | ABBVIE CORPORATION | MARKETED | DIN 02539721 |
Who else supplies UPADACITINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. UPADACITINIB appears in 59 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.